US2762746A - Composition for combating malaria and process of making same - Google Patents

Composition for combating malaria and process of making same Download PDF

Info

Publication number
US2762746A
US2762746A US320624A US32062452A US2762746A US 2762746 A US2762746 A US 2762746A US 320624 A US320624 A US 320624A US 32062452 A US32062452 A US 32062452A US 2762746 A US2762746 A US 2762746A
Authority
US
United States
Prior art keywords
salt
coating
wax
compound
polyethylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US320624A
Inventor
John O Barnett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Priority to US320624A priority Critical patent/US2762746A/en
Application granted granted Critical
Publication of US2762746A publication Critical patent/US2762746A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention relates to a new therapeutic composition which is effective in combating malaria. It is also concerned with a new and improved process by which the new antimalarial composition may be prepared.
  • compositions for combating the disease in the usual manner by supplying pills, capsules, tablets, etc. of a solid composition which is effective against the malarial organism for ingestion by persons who may be sufiering with the disease.
  • the compound 8 (4 amino-l-methylbutylamino)-6- methoxyquinoline, known as Primaquine, is described in the Journal of the American Chemical Society, vol. 68, page 1525 (1946).
  • the homogeneous and uniform dispersion of the organic antimalarial compound is ordinarily essential, for it is very desirable that different samples of the table salt shall contain substantially the same proportion of the antimalarial compound distributed throughout the sample. Since an antimalarial. compound, such as any one of the three compounds mentioned, is eflective in proportions ranging from 1 part of the organic compound in 5,000 parts of table salt, to 1 part of the Organic compound in 500 parts of table salt, based on the average daily consumption of salt it is obviously not easy to secure uniform distribution of the organic compound in the salt in such relatively dilute concentrations. 7
  • an antimalarial compound such as 2,4-cliamino-S-p-chlorophenyl-6-ethylpyrimidine, 8-(4-amino-l-methylbutylamino)-6-methoxyquinoline, or '7-chloro-4-(4-diethylaminol-methylbutylamino) quinoline
  • the antimalarial being present only in minor amount on a relatively very much larger amount of salt, the resulting product is not satisfactory from the point of view of particle separation.
  • table salt is relatively hygroscopic in character, tending to cake when stored in a humid atmosphere. This tendency to cake, especially when stored under moist climatic conditions, renders the product less satisfactory from a dietary point of view.
  • a medicament is administered as a coating on a lumpy unattractive food seasoning, it is diiiicult to insure adequate medication by the ingestion of uniform and effective quantities of the antimalarial along with the salt.
  • the coated product containing the agent efiective against malaria is more desirable as a table seasoning or condiment, as it is substantially nonhygroscopic and exhibits little or no tendency to cake, even upon storage under relatively moist conditions.
  • one of the three organic antimalarials 2,4 diamino-S-p-chlorophenyl-6-ethylpyrimidine (Daraprim); 8-(4-amino-l-methylbutylamino)- G-rnethoxyquinoline (Primaquine); or 7-chloro-4-(4-diethylamino 1 methylbutylamino)quinoline (Chloroquine), is employed.
  • the wax-like solid with which the salt crystals are first coated must be one that does not appreciably affect the taste of the resulting product, and which is devoid of any objectionable odor. While various water-soluble, wentlike solid products that are available might be utilized, I prefer first to coat the salt crystals with a commercially available product, which is chemically identified as polyethylene glycol having a molecular weight in excess of about 1,000. Wax-like polyethylene glycol products of this type, substantially devoid of odor and taste, and nonhygroscopic even when stored under humid conditions, are sold by Carbide & Carbon Chemicals Corporation as Carbowax 6,000. Other polyethylene glycol solid products bearing different trade designations may also be used.
  • the amount of polyethylene glycol having a molecular weight in excess of 1,000 which should be applied as a primary coating to the salt will generally vary with the particular concentration of antimalarial which is desired on the coated salt product. For concentrations of 1 part by weight of the antimalarial compound in 1,000 parts by weight of salt, or less, I prefer to apply as the primary coating about 1.25 parts by weight of the polyethylene glycol solid wax-like, water-soluble, non-hygroscopic solid product for each 1,000 parts by weight of salt. If the antimalarial is to be present in a higher concentration, in excess of 1 part of organic antimalarial compound per 1,000 parts of salt, the amount of polyethylene glycol wax-like solid applied to the salt as the primary coating should be increased.
  • the amount of polyethylene glycol wax-like solid used to coat the salt in the primary coating may range up to 2.5 parts of polyethylene glycol per 1,000 parts of salt.
  • Coating the poylethylene glycol having a molecular weight in excess of about 1,000 on the salt crystals as a water-soluble, wax-like primary coating is best accomplished by applying to the salt a solution containing the desired amount of the wax-like solid dissolved in a suitable volatile solvent, such as an alcohol, one of the lower alkanols being preferred. This may advantageously be;
  • the salt is then dried by the passage of a current of air over it while it is still in the revolving pan, followed by transference to a drying oven and evaporation off of residual solvent at a temperature of approximately 50 C.
  • the sodium chloride may be transferred directly to a drying oven and the entire operation of drying carried out in the oven.
  • the table salt After the table salt has been coated with the primary layer of wax-like solid, it is preferably returned to the coating pan for treatment with a solution of the organic antimalarial compound, the purpose being to attach the antimalarial compound directly on the wax-like layer. It is usually first desirable to pass the salt with its primary coating through a sieve, as for example through one of standard No. 16 mesh, in order to eliminate undesirable large particles.
  • the required amount of the antimalarial agent, 2,4-diamino-5-p-chlorophenyl-6-ethylpyrimidine in the procedure herein given as typical be weighed out, based on the weight of salt to be coated, and the antimalarial then dissolved in a volatile solvent such as acetone. Other organic solvents may also be used.
  • the solution of Daraprim is added to the salt, preferably while the latter is retained in a revolving pan, and the solution is best applied to the coated salt in successive small amounts not all at once.
  • the salt may then be dried by the passage of air over it while it is on the re volving pan, followed by transference to a drying oven where drying may be continued at a temperature of approximately 40 C. to eliminate the last traces of the volatile solvent. If desired, the entire drying operation may be carried out in a heated oven at a moderately elevated temperature, a temperature of about 40 C. having been found very satisfactory.
  • the dried salt is then sieved to remove large particles, as by passing it through a standard screen of No. 16 mesh. It is then packaged, and is available for use to supply therapeutically-effective blood levels of the antimalarial compound to persons who ingest the salt as seasoning on their daily supply of food, or who may consume salt for any other purpose.
  • Example 1 To 1,000 grams of table salt on a revolving pan type of coating machine, there was added a solution containing 1.25 grams of Carbowax 6,000 dissolved in 25 milliliters of ethyl alcohol.
  • Carbowax 6,000 is a trade designation for polyethylene glycol having a molecular weight 7 weight.
  • the solution was added in incremental amounts of 20 milliliters each time e salilwhish as relat d 9n the Pa d dried b fi js Y urr nt Q a r ass ng ove it after a P- plication of the solution.
  • the coated salt was spread on trays and dried in a drying ovenat a ten iperature of 40 C.
  • the completely 'dry product wasthen' sieved to pass through a standard No. 16 sieve, and packaged.
  • the resulting product was a non-caking, white, odorless product wherein the individual salt crystals were sur rounded and protected by a white wax-like coating.
  • the antimalarial compound i. e. 2,4-diamino-5-p-chlorophenyl-6-ethylpyrimidine, was securely retained on the salt crystals, being bonded to them by means of the waxlike primary coating.
  • the product tasted like ordinary table salt, and was free of any foreign taste.
  • the antimalarial compound in the amount of 0.1% by weight, was evenly distributed throughout the entire mass of salt, being supported by the individual salt crystals.
  • coated sodium chloride products containing any desired level of 2,4-diamino-S-p-chlorophcnyl-6-ethylpyrimidine ranging from 0.1 part of antimalarial compound per 1,000 grams of salt to 2 parts of antimalarial compound per 1,000 grams of salt, these ratios being by
  • the other antimalarials, 8-(4-amino-1-methylbutylamino)-6-methoxyquinoline, or 7-chloro-4-(4-diethylarnino-l-methylbutylamino) quinoline are applied in the same manner to the salt coated with the primary waxlike coating, the proportions of antimalarial to salt falling within the range specified.
  • the process of preparing a therapeutic composition effective against malaria which comprises coating sodium chloride salt particles with polyethylene glycol having a molecular weight in excess of about 1,000 to provide an adherent coating of wax-like material thereon, and then uniformly applying to said coated salt a solid compound possessing activity against malaria so that said compound is uniformly dispersed on said wax-like coating and thereby retained on said salt.
  • the process of preparing a therapeutic composition effective against malaria which comprises coating sodium chloride salt particles with polyethylene glycol havin a mo sula We in x es o abs 000 to an): vide'an adherent primary coating of a wax-like'rnaterial on said salt, and then uniformly'applying tosaid coated salt an antimalarial selected from the group which con-. sists of 2,4 diamino-S-p-chlorophenyl-dethylpyrimidine, 8-(4-amino-l methylbutylamino) 6 methoxyquinoline, and 7-chloro-4-(4-diethylamino l methylbutylamino ⁇ in in r 3.
  • the process of preparing a therapeutic composition effective against malaria which comprises coating sodium chloride salt particles with polyethylene glycol having a molecular weight in excess of about 1,000 to provide an adherent primary coating of a wax-like material on said salt, and then uniformly applying to said coated salt 2,4-diarnino 5 p chlorophenyl-6-ethylpyrimidine so that said compound is uniformly dispersed on said like coating and thereby retained on said salt;
  • the process of preparing a therapeutic composition effective against malaria which comprises coating sodium chloride salt particles with polyethylene glycol having a molecular weight in excess of about 1,000 to provide an adherent primary coating of a wax-like material on said salt, and then uniformly applying to said coated salt 7- 1chloro-'4-(diethylamino'l-methylbutylamino)quinoline so that said compound is uniformly dispersed on said waxlike coating and thereby retained on said salt.
  • Particles comprising sodium chloride crystals coated with a primary coating of polyethylene glycol having a molecular weight in excess of about 1,000 and a secondary coating of 2,4-d-iamino-5-pchlorophenyl-6ethylpyrimidine adhering to said polyethylene glycol layer on said particles.
  • Particles comprising sodium chloride crystals coated with a primary coating of polyethylene glycol having a molecular weight in excess of about 1,000 and a secondary coating of 8 ('4 amino- 1-methylbutylamino)-6-methoxyquinoline adhering to said polyethylene glycol layer on said particles.
  • Particles comprising sodium chloride crystals coated With a primary coating of polyethylene glycol having a molecular weight in excess of about 1,000 and a secondary coating of 7 chloro-4-*(4-diethylamino l-methylbutylamino)quinoline adhering to said polyethylene glycol layer on said particles.
  • the process of preparing a therapeutic composition effective against malaria which comprises coating sodium chloride salt particles with polyethylene glycol having a molecular weight in excess of about 1,000 while said salt is retained on a revolving surface, thereby providing !E1Il adherent primary coating of a Wax-like material on said salt, and then uniformly applying to said coated salt an anti-malarial selected from the group which consists of 2,4-diamino-5 p chlorophenyl-6-ethylpyrimidine, 8-(4- .amino-l-methylbutylamino)-6-methoxyquinoline, and 7- chloro-4-(4 diethylamino-l-methylbutylamino)quinoline while said salt provided with said primary coating is retained on a revolving surface.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

COMPOSITION FOR COMBATING MALARIA AND PRoCEss OF MAKING SAME John O. Barnett, Philadelphia, Pa., assignor, by mesne assignments, to American Home Products Corporation, New York, N. Y., a corporation of Delaware No Drawing. Application November 14, 1952, Serial No. 320,624
12 Claims. (Cl. 167-65) This invention relates to a new therapeutic composition which is effective in combating malaria. It is also concerned with a new and improved process by which the new antimalarial composition may be prepared.
In the treatment of malaria, particularly in regions where it is endemic, it is frequently difficult, and sometimes impossible, to administer compositions for combating the disease in the usual manner by supplying pills, capsules, tablets, etc. of a solid composition which is effective against the malarial organism for ingestion by persons who may be sufiering with the disease.
In many cases persons who suiferwith malaria have a definite aversion to taking medicinals of any sortwhich would help in combating their infection. While this aversion is sometimes more prevalent among persons of relatively more primitive culture, objections to the ingestion of therapeutic agents in the form of pills, tablets, capsules, other forms of solid medicament, etc., are often encountered even among more educated persons.
Even where objections to the taking of therapeutic agents by mouth are not experienced, there are frequently definite advantages in being able to administer medicaments incorporated on a foodstuff, condiment, or other article of diet, so that the active material may be taken orally along with other substances at meal times, no separate ingestion of therapeutic agents being required. This has previously been accomplished to some States Patent extent with some types of pharmaceutical preparations,
but it has ordinarily not been successful Where a relatively very small amount of a solid therapeutic agent is to be distributed throughout a much larger amount of a solid material of a powdered or granular character, such as table salt, sugar, rice, or similar solid carrier.
Among those solid materials of a food or condiment character which might be used as a base or carrier to support a therapeutic agent, such as an organic compound effective against malaria, so that the anti-malarial agent could be administered along with the dietary material, ordinary table salt would appear to be among the more promising. Salt is consumed as a part of the regular diet, both by those persons who are generally more receptive totaking medication by mouth, as well as by those of a more primitive culture who are frequently more diflicult to convince as to the desirability of taking medication for malaria. Since malaria is endemic in many areas which are deficient in medical facilities and which are inhabited by native populations diflicult to reach with medication, it is evident that the administration of an antimalarial compound along with the daily intake of salt would be advantageous from many points of view. Ellective antimalarial agents, if homogeneously dispersed throughout the table salt, and if no objectionable taste or odor were imparted thereto by the additive,'could be thus rendered more widely available, both to persons who are located in inaccessible places, reachable by medical oflicials only with difiiculty, as well as to persons who aremore fortunately situated with reference to medical facilities.
While compounds effective in the treatment of malaria are now available, some of them such as 2,4-diamino-5-pchlorophenyl 6 ethylpyrimidine, 8-(4-amino-l-methylbutylamino)-6-rnethoxyquinoline, and 7-chloro-4-(4-diethylamino-l-methylbutylamino)quinoline being especially active, many of these compounds are effective in such relatively small dosages that the homogeneous dispersion of the small amount of antimalarial compound necessary throughout a much larger amount of a carrier material, such as ordinary table salt, is a very difficult operation.
The compound 2,4-diamino-5-p-chlorophenyl-6-ethylpyrimidine, known as Daraprim, is described in Patent No. 2.576,939.
The compound 8 (4 amino-l-methylbutylamino)-6- methoxyquinoline, known as Primaquine, is described in the Journal of the American Chemical Society, vol. 68, page 1525 (1946). The compound 7-chloro-4-(4-diethylamino-l-methylbutylamino)quinoline, known as Chloroquine, is described in Patent No. 2,233,970. All three compounds, as well as their salts, are potent antimalarials. Whenever they are referred to herein, it is my intention that the named chemical compounds shall also denote the salts of the bases, since they are frequently administered in the form of their salts.
The homogeneous and uniform dispersion of the organic antimalarial compound is ordinarily essential, for it is very desirable that different samples of the table salt shall contain substantially the same proportion of the antimalarial compound distributed throughout the sample. Since an antimalarial. compound, such as any one of the three compounds mentioned, is eflective in proportions ranging from 1 part of the organic compound in 5,000 parts of table salt, to 1 part of the Organic compound in 500 parts of table salt, based on the average daily consumption of salt it is obviously not easy to secure uniform distribution of the organic compound in the salt in such relatively dilute concentrations. 7
When an antimalarial compound is coated directly on table salt, separation of the compound from the salt in the form of fines usually occurs when the coated product is subjected to even a moderate amount of vibration. This tendency of the smaller-sized particles to drop to the bottom of the container is common with powders which vary in particle size. if an effort is made to coat table salt directly with an antimalarial compound, such, for example, as 2,4-cliamino-S-p-chlorophenyl-6-ethylpyrimidine, 8-(4-amino-l-methylbutylamino)-6-methoxyquinoline, or '7-chloro-4-(4-diethylaminol-methylbutylamino) quinoline, the antimalarial being present only in minor amount on a relatively very much larger amount of salt, the resulting product is not satisfactory from the point of view of particle separation. This is true when a conventional coating method is used, such as deposition of the antimalarial compound on the salt by wetting the table salt with a solution of the antimalarial in an organic solvent, followed by drying the wetted salt. The active compound is so loosely held on the salt crystals, and is so dispersed throughout the mass of a very much larger volume of salt, that it is easily shaken loose there from to separate as an objectionable fine layer in the bottom of the container.
Moreover table salt is relatively hygroscopic in character, tending to cake when stored in a humid atmosphere. This tendency to cake, especially when stored under moist climatic conditions, renders the product less satisfactory from a dietary point of view. When a medicament is administered as a coating on a lumpy unattractive food seasoning, it is diiiicult to insure adequate medication by the ingestion of uniform and effective quantities of the antimalarial along with the salt.
I have now found that it is possible to disperse a very CD small amount of an antimalarial compound throughout a much larger amount of table salt in such a manner as to secure uniform and homogeneous dispersion thereof provided the salt crystals are first given a coating of a wax-like, water-soluble, non-hygroscopic solid, the organic compound active against malaria being then attached to this wax-like surface coating on the salt crystals. Moreover by first forming on the salt a primary coating of wax-like character, the organic antimalarial compound has been found to adhere more satisfactorily to the wax-coated salt, so that separation of fine particles from the mixture as a result of vibration is almost completely avoided. This is due to the adhesiveness of the wax-like solid, an inherent property which results in the medicinal firmly adhering to the wax-like, watersoluble, non-hygroscopic solid, and thence to the coated salt crystals or particles. When the salt crystals are provided with a protective primary layer of wax-like, nonhygroscopic material, the coated product containing the agent efiective against malaria is more desirable as a table seasoning or condiment, as it is substantially nonhygroscopic and exhibits little or no tendency to cake, even upon storage under relatively moist conditions.
As the antimalarial compound with which the table salt is to be coated, and which compound adheres to and is substantially uniformly distributed on the primary coating of wax-like, water-soluble, non-hygroscopic solid which surrounds the salt crystals, one of the three organic antimalarials: 2,4 diamino-S-p-chlorophenyl-6-ethylpyrimidine (Daraprim); 8-(4-amino-l-methylbutylamino)- G-rnethoxyquinoline (Primaquine); or 7-chloro-4-(4-diethylamino 1 methylbutylamino)quinoline (Chloroquine), is employed.
The wax-like solid with which the salt crystals are first coated must be one that does not appreciably affect the taste of the resulting product, and which is devoid of any objectionable odor. While various water-soluble, wentlike solid products that are available might be utilized, I prefer first to coat the salt crystals with a commercially available product, which is chemically identified as polyethylene glycol having a molecular weight in excess of about 1,000. Wax-like polyethylene glycol products of this type, substantially devoid of odor and taste, and nonhygroscopic even when stored under humid conditions, are sold by Carbide & Carbon Chemicals Corporation as Carbowax 6,000. Other polyethylene glycol solid products bearing different trade designations may also be used.
The amount of polyethylene glycol having a molecular weight in excess of 1,000 which should be applied as a primary coating to the salt will generally vary with the particular concentration of antimalarial which is desired on the coated salt product. For concentrations of 1 part by weight of the antimalarial compound in 1,000 parts by weight of salt, or less, I prefer to apply as the primary coating about 1.25 parts by weight of the polyethylene glycol solid wax-like, water-soluble, non-hygroscopic solid product for each 1,000 parts by weight of salt. If the antimalarial is to be present in a higher concentration, in excess of 1 part of organic antimalarial compound per 1,000 parts of salt, the amount of polyethylene glycol wax-like solid applied to the salt as the primary coating should be increased. When the antimalarial is present in amounts up to 0.2% by Weight (2.0 milligrams per gram of salt), the amount of polyethylene glycol wax-like solid used to coat the salt in the primary coating may range up to 2.5 parts of polyethylene glycol per 1,000 parts of salt.
Coating the poylethylene glycol having a molecular weight in excess of about 1,000 on the salt crystals as a water-soluble, wax-like primary coating is best accomplished by applying to the salt a solution containing the desired amount of the wax-like solid dissolved in a suitable volatile solvent, such as an alcohol, one of the lower alkanols being preferred. This may advantageously be;
carried out while the salt is retained in a revolving coating pan.
It is ordinarily advantageous to add the solution of wax-like, water-soluble, non-hygroscopic solid to the salt in the form of several small portions, rather than to add the entire solution all at once. The salt is then dried by the passage of a current of air over it while it is still in the revolving pan, followed by transference to a drying oven and evaporation off of residual solvent at a temperature of approximately 50 C. Alternatively, after being wet with the solution of the wax-like solid in a solvent such as ethyl alcohol, the sodium chloride may be transferred directly to a drying oven and the entire operation of drying carried out in the oven.
Among alcohols in which polyethylene glycol having a molecular weight in excess of about 1,000 is soluble, good results have been secured both with ethyl alcohol and isopropyl alcohol. Heating may be advantageous in order to bring the polyethylene glycol into solution in the alcohol. However, the solution should ordinarily be cooled to a temperature within the range 25-30 C. before it is applied to the salt.
After the table salt has been coated with the primary layer of wax-like solid, it is preferably returned to the coating pan for treatment with a solution of the organic antimalarial compound, the purpose being to attach the antimalarial compound directly on the wax-like layer. It is usually first desirable to pass the salt with its primary coating through a sieve, as for example through one of standard No. 16 mesh, in order to eliminate undesirable large particles.
The application of 2,4-diamino-5-p-chlorophenyl-6- ethylpyrirnidine (Daraprim) to table salt may be considered as a typical procedure, as exactly the same procedure, would be used if one of the other antimalarial compounds, i. e. 8-(4-amino-l-methylbutylamino)-6- methoxyquinoline (Primaguine); or 7 chloro 4 (4-diethylamino-l-methylbutylamino) quinoline (Chloroquine) were coated on the salt.
It is desirable that the required amount of the antimalarial agent, 2,4-diamino-5-p-chlorophenyl-6-ethylpyrimidine in the procedure herein given as typical, be weighed out, based on the weight of salt to be coated, and the antimalarial then dissolved in a volatile solvent such as acetone. Other organic solvents may also be used. The solution of Daraprim is added to the salt, preferably while the latter is retained in a revolving pan, and the solution is best applied to the coated salt in successive small amounts not all at once. The salt may then be dried by the passage of air over it while it is on the re volving pan, followed by transference to a drying oven where drying may be continued at a temperature of approximately 40 C. to eliminate the last traces of the volatile solvent. If desired, the entire drying operation may be carried out in a heated oven at a moderately elevated temperature, a temperature of about 40 C. having been found very satisfactory.
The dried salt is then sieved to remove large particles, as by passing it through a standard screen of No. 16 mesh. It is then packaged, and is available for use to supply therapeutically-effective blood levels of the antimalarial compound to persons who ingest the salt as seasoning on their daily supply of food, or who may consume salt for any other purpose.
As illustrative of the production of my new therapeutic composition, in accordance with my invention, the following detailed procedure, setting forth the amounts employed, may be given.
Example To 1,000 grams of table salt on a revolving pan type of coating machine, there was added a solution containing 1.25 grams of Carbowax 6,000 dissolved in 25 milliliters of ethyl alcohol. Carbowax 6,000 is a trade designation for polyethylene glycol having a molecular weight 7 weight.
in mess of 1,000- T e l ti n wa a ded. t thesa t in several successive divided applicatihn and not. at once. a
The sodium chloride, wet with the solution of polyethylene glycol, was then partially dried with a current of air while still in motion on the revolving coating pan. It was then transferred to trays and'dried at a temperature of 50 C. in a drying oven. It was cooled, and i v 9 1 .5 ou h a s anda 6 me siev Thedried table salt, the individual crystals of which were coated with the white wax-like coating, were then r rn o h coati P n for app ica i of he ant a ri mlao nd- -diamiu -P- p e y1- e r m ie in e m n of 1 a s h n'di solved in 300 milli 'ters of acetone. The solution was added in incremental amounts of 20 milliliters each time e salilwhish as relat d 9n the Pa d dried b fi js Y urr nt Q a r ass ng ove it after a P- plication of the solution.
After all of the acetone solution of Daraprirn had been added, and the salt subjected to preliminary drying by means of a current of air, the coated salt was spread on trays and dried in a drying ovenat a ten iperature of 40 C. The completely 'dry productwasthen' sieved to pass through a standard No. 16 sieve, and packaged.
The resulting product was a non-caking, white, odorless product wherein the individual salt crystals were sur rounded and protected by a white wax-like coating. The antimalarial compound, i. e. 2,4-diamino-5-p-chlorophenyl-6-ethylpyrimidine, was securely retained on the salt crystals, being bonded to them by means of the waxlike primary coating. When placed in the mouth, the product tasted like ordinary table salt, and was free of any foreign taste.
When the product was stored under moist conditions, no appreciable amount of cake was apparent. It showed no tendency to separate into particles of varying particle size when the packaged product was subjected to vibration.
The antimalarial compound, in the amount of 0.1% by weight, was evenly distributed throughout the entire mass of salt, being supported by the individual salt crystals.
By following a similar procedure, it is possible to prepare coated sodium chloride products containing any desired level of 2,4-diamino-S-p-chlorophcnyl-6-ethylpyrimidine ranging from 0.1 part of antimalarial compound per 1,000 grams of salt to 2 parts of antimalarial compound per 1,000 grams of salt, these ratios being by The other antimalarials, 8-(4-amino-1-methylbutylamino)-6-methoxyquinoline, or 7-chloro-4-(4-diethylarnino-l-methylbutylamino) quinoline, are applied in the same manner to the salt coated with the primary waxlike coating, the proportions of antimalarial to salt falling within the range specified.
Since various changes and modifications may be made in my invention as disclosed herein without departing from the scope thereof, it is my intention that such changes and modifications as may be within the scope of the appended claims will be regarded as part of my invention.
I claim:
1. The process of preparing a therapeutic composition effective against malaria, which comprises coating sodium chloride salt particles with polyethylene glycol having a molecular weight in excess of about 1,000 to provide an adherent coating of wax-like material thereon, and then uniformly applying to said coated salt a solid compound possessing activity against malaria so that said compound is uniformly dispersed on said wax-like coating and thereby retained on said salt.
2. The process of preparing a therapeutic composition effective against malaria which comprises coating sodium chloride salt particles with polyethylene glycol havin a mo sula We in x es o abs 000 to an): vide'an adherent primary coating of a wax-like'rnaterial on said salt, and then uniformly'applying tosaid coated salt an antimalarial selected from the group which con-. sists of 2,4 diamino-S-p-chlorophenyl-dethylpyrimidine, 8-(4-amino-l methylbutylamino) 6 methoxyquinoline, and 7-chloro-4-(4-diethylamino l methylbutylamino} in in r 3. The process of preparing a therapeutic composition effective against malaria which comprises coating sodium chloride salt particles with polyethylene glycol having a molecular weight in excess of about 1,000 to provide an adherent primary coating of a wax-like material on said salt, and then uniformly applying to said coated salt 2,4-diarnino 5 p chlorophenyl-6-ethylpyrimidine so that said compound is uniformly dispersed on said like coating and thereby retained on said salt;
4- he P e of p p i a hera eu 'c mpos ti effective against malaria which comprises coating'sodiurn chloride salt particles with polyethylene'glycol having a molecular weight in excess of about 1,000 to proyide an adherent primary coating of a wax-like material on said salt, and then uniformly applying to said coated salt 8-.( m.in9 1 hy b v i )-6-m h yquinc in So that said ompo d s u o dispe sed n said wax-like c'oating'and thereby retained on said salt;
5. The process of preparing a therapeutic composition effective against malaria which comprises coating sodium chloride salt particles with polyethylene glycol having a molecular weight in excess of about 1,000 to provide an adherent primary coating of a wax-like material on said salt, and then uniformly applying to said coated salt 7- 1chloro-'4-(diethylamino'l-methylbutylamino)quinoline so that said compound is uniformly dispersed on said waxlike coating and thereby retained on said salt.
6. Sodium chloride particles coated with an adherent primary coating of polyethylene glycol having a molecular weight in excess of about 1,000, and a layer of a solid compound possessing activity against malaria positioned on said coated particles and adhering to said polyethylene glycol layer thereon.
7. Particles comprising sodium chloride crystals coated with a primary coating of polyethylene glycol having a molecular weight in excess of about 1,000 and a secondary coating of 2,4-d-iamino-5-pchlorophenyl-6ethylpyrimidine adhering to said polyethylene glycol layer on said particles.
8. Particles comprising sodium chloride crystals coated with a primary coating of polyethylene glycol having a molecular weight in excess of about 1,000 and a secondary coating of 8 ('4 amino- 1-methylbutylamino)-6-methoxyquinoline adhering to said polyethylene glycol layer on said particles.
9. Particles comprising sodium chloride crystals coated With a primary coating of polyethylene glycol having a molecular weight in excess of about 1,000 and a secondary coating of 7 chloro-4-*(4-diethylamino l-methylbutylamino)quinoline adhering to said polyethylene glycol layer on said particles.
10. The process of preparing a therapeutic composition effective against malaria which comprises coating sodium chloride salt particles with polyethylene glycol having a molecular weight in excess of about 1,000 while said salt is retained on a revolving surface, thereby providing !E1Il adherent primary coating of a Wax-like material on said salt, and then uniformly applying to said coated salt an anti-malarial selected from the group which consists of 2,4-diamino-5 p chlorophenyl-6-ethylpyrimidine, 8-(4- .amino-l-methylbutylamino)-6-methoxyquinoline, and 7- chloro-4-(4 diethylamino-l-methylbutylamino)quinoline while said salt provided with said primary coating is retained on a revolving surface.
1 1. The process of preparing a therapeutic composition effective against malaria which comprises coating sodium chloride salt particles by applying thereto a solution of polyethylene glycol having a molecular weight in excess of about 1,000 in a volatile organic solvent while said salt is positioned on a revolving surface, drying said salt in order to remove said volatile organic solvent therefrom by passing a current of air thereover .while said salt is on said revolving surface, uniformly applying to said salt coated with an adherent primary coating of said polyethylene glycol thereon a solution of an antimalarial selected from the group which consists of 2,4di:a.mino-5- p-chloropheny-l-6-ethylpyrimidine, 8-(4 amino-l-methylbutyl-amino)-6-methoxyquinoline, and 7 chloro-4-(4-diethylamino-1-methylbutylamino)quinoline while said salt is on the revolving surface, and drying said salt by passing a current of air thereover while said salt is on said revolving surface in order to remove excess solvent therefrom, whereby salt particles wherein said antimalarial is firmly attached to said polyethylene glycol coating, and said polyethylene glycol coating is firmly attached to said salt, are secured.
12. Sodium chloride particles coated with an adherent primary coating of polyethylene glycol having a molecular weight in excess of about 1,000, and a layer of a compound possessing activity against malaria positioned on said coated particles and adhering to said polyethylene glycol layer thereon, said compound being one selected firom the group which consists of 2,4-diamino-5-pchloro phenyl-6-ethy1pyrimidine, 8-(4 amino 1 methylbutylamino)-6-methoxyquinoli-ne, and 7-ch1oro 4-(4-diethylamino-'1 -methylbutylamino) quinoline.
References Cited in the file of this patent UNITED STATES IATENTS 1,463,881 Farrell Aug. 7, 1923 2,146,867! Wclin Feb. 14,11939 2,149,005 Bockmuhl Feb. 28, 1939 2,233,970 Andersag et ai. Mar. 4,1941 2,455,749 Fonyo Dec. 7, 1948 2,497,057 Pape Feb. 7, 1950 2,539,012 Diamond et al. Jan. 23, 1951 2,540,253 Gakenh-eimer Feb. 6, 1951 2,576,939 Hitchings et al. Dec. 4,1951 2,579,732 Funsten et a1 Dec. 25, 1951 2,645,581 Robison July 14, 1953 OTHER REFERENCES Schertz: In-d. and Eng. Chem, vol. 19, No.10, October 1927, pages 1152*1153.
J. A. C. 8., volume 68, page 1525, 1946.

Claims (1)

1. THE PROCESS OF PREPARING A THERAPEUTIC COMPOSITION EFFECTIVE AGAINST MALARIA, WHICH COMPRISES COATING SODIUM CHLORIDE SALT PARTICLES WITH POLYETHYLENE GLYCOL HAVING A MOLECULAR WEIGHT IN EXCESS OF ABOUT 1,000 TO PROVIDE AN ADHERENT COATING OF WAX-LIKE MATERIAL THEREON, AND THEN UNIFORMLY APPLYING TO SAID COATED SALT A SOLID COMPOUND POSSESSING ACTIVITY AGAINST MALARIA SO THAT SAID COMPOUND IS UNIFORMLY DISPERSED ON SAID WAX-LIKE COATING AND THEREBY RETAINED ON SAID SALT.
US320624A 1952-11-14 1952-11-14 Composition for combating malaria and process of making same Expired - Lifetime US2762746A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US320624A US2762746A (en) 1952-11-14 1952-11-14 Composition for combating malaria and process of making same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US320624A US2762746A (en) 1952-11-14 1952-11-14 Composition for combating malaria and process of making same

Publications (1)

Publication Number Publication Date
US2762746A true US2762746A (en) 1956-09-11

Family

ID=23247229

Family Applications (1)

Application Number Title Priority Date Filing Date
US320624A Expired - Lifetime US2762746A (en) 1952-11-14 1952-11-14 Composition for combating malaria and process of making same

Country Status (1)

Country Link
US (1) US2762746A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3048525A (en) * 1958-01-20 1962-08-07 Baugh Charles Salt composition and process for making same
US3082154A (en) * 1960-04-19 1963-03-19 Ici Ltd Improved free-flowing coated antimalarial salts in particulate form
US20140154508A1 (en) * 2010-05-11 2014-06-05 Allergan, Inc. Porogen compositions, methods of making and uses
US9522502B2 (en) 2010-09-28 2016-12-20 Allergan, Inc. Porous materials, methods of making and uses

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1463881A (en) * 1922-08-08 1923-08-07 Eben E Olcott Process and product of preparing stearate of zinc for use in relieving prickly heat,etc.
US2146867A (en) * 1937-06-07 1939-02-14 Welin Sater Company Medicinal preparation and method of making the same
US2149005A (en) * 1935-11-09 1939-02-28 Winthrop Chem Co Inc Shaped medicinal preparation
US2233970A (en) * 1941-03-04 Quinoline compound and process of
US2455749A (en) * 1946-03-15 1948-12-07 Wm J Stange Co Condiment
US2497057A (en) * 1950-02-07 Toilet bowl -gleanee
US2539012A (en) * 1948-08-11 1951-01-23 Gen Foods Corp Salt product
US2540753A (en) * 1945-03-03 1951-02-06 Westinghouse Air Brake Co Combination valve and switch mechanism
US2576939A (en) * 1951-12-04 -diamino-s-phenyl-e-alkyl-
US2579732A (en) * 1946-09-20 1951-12-25 Filtrol Corp Coated seed
US2645581A (en) * 1949-04-26 1953-07-14 Morton Salt Co Antioxidant salt and method of preparing the same

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2233970A (en) * 1941-03-04 Quinoline compound and process of
US2497057A (en) * 1950-02-07 Toilet bowl -gleanee
US2576939A (en) * 1951-12-04 -diamino-s-phenyl-e-alkyl-
US1463881A (en) * 1922-08-08 1923-08-07 Eben E Olcott Process and product of preparing stearate of zinc for use in relieving prickly heat,etc.
US2149005A (en) * 1935-11-09 1939-02-28 Winthrop Chem Co Inc Shaped medicinal preparation
US2146867A (en) * 1937-06-07 1939-02-14 Welin Sater Company Medicinal preparation and method of making the same
US2540753A (en) * 1945-03-03 1951-02-06 Westinghouse Air Brake Co Combination valve and switch mechanism
US2455749A (en) * 1946-03-15 1948-12-07 Wm J Stange Co Condiment
US2579732A (en) * 1946-09-20 1951-12-25 Filtrol Corp Coated seed
US2539012A (en) * 1948-08-11 1951-01-23 Gen Foods Corp Salt product
US2645581A (en) * 1949-04-26 1953-07-14 Morton Salt Co Antioxidant salt and method of preparing the same

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3048525A (en) * 1958-01-20 1962-08-07 Baugh Charles Salt composition and process for making same
US3082154A (en) * 1960-04-19 1963-03-19 Ici Ltd Improved free-flowing coated antimalarial salts in particulate form
US20140154508A1 (en) * 2010-05-11 2014-06-05 Allergan, Inc. Porogen compositions, methods of making and uses
US9522502B2 (en) 2010-09-28 2016-12-20 Allergan, Inc. Porous materials, methods of making and uses

Similar Documents

Publication Publication Date Title
US2921883A (en) Novel coating material for medicaments
US3082154A (en) Improved free-flowing coated antimalarial salts in particulate form
US2410417A (en) Vitamin and mineral dietary supplement and method of making
US3539380A (en) Methylcellulose and polyalkylene glycol coating of solid medicinal dosage forms
EP0285682B1 (en) Process for the manufacture of vitamin preparations
US3256111A (en) Method for coating tablets
US3131068A (en) Water-soluble coated edible organic acids
US2508477A (en) Enriched foodstuffs
US3037911A (en) Chewable, palatable, vitamin b preparations
US2854379A (en) Tranquilizing composition comprising 2-ethyl-cis-crotonylurea
KR960015137B1 (en) Stabilized feed additive and process for the preparation thereof
KR101104502B1 (en) Humidity-dependent antibacterial powdery composition, process for producing the same, humidity- dependent antibacterial food storing article and method of storing food
US2762746A (en) Composition for combating malaria and process of making same
JP2922967B2 (en) Composition of vitamin B group compound and method for producing the same
SE433170B (en) PROCEDURE FOR PREPARING A PHARMACOLOGICAL ACCEPTABLE COMPOSITION COMPREHENSIVE HYGROSCOPIC POLY - / (METHYL- (3-TRIMETYLAMMONIOPROPYL) IMINIO) TRIMETYLENE-DICHLORIDE /
US3300387A (en) Pressed powder antiperspirant and method of preparation
EP0168360A3 (en) Process for preparing etofibrate or similar compounds containing sustained release microgranules and products thus obtained
US3279994A (en) Riboflavin beadlet composition
US2844512A (en) Fumagillin enveloped in fatty or waxy substance and enclosed in ultraviolet opaque container
EP0321457A1 (en) Aqueous dispersions of waxes and lipids for pharmaceutical coating
US3398225A (en) Coated 2, 2-dichlorovinyl phosphate and polyvinyl chloride resin anthelmintic compositions
JP2524602B2 (en) Soft capsule
US5730912A (en) Method of the encapsulation of liquids
US3067105A (en) Vitamin compositions and processes for producing same
US3433872A (en) Palatable,free-flowing,non-agglomerating caffeine powder